尼日尔儿童生存阿奇霉素群体给药后抗菌药物耐药性向未治疗7-12岁儿童溢出的评估:MORDOR整群随机试验的二次分析
该研究基于MORDOR整群随机试验,比较每半年一次向1-59月龄儿童分发阿奇霉素与安慰剂对儿童死亡率的影响,并检测未治疗7-12岁儿童鼻咽样本中大环内酯类耐药遗传决定因素(主要结局)及其他抗生素类别耐药(次要结局)。24个月时,阿奇霉素组与安慰剂组社区层面耐药决定因素患病率经基线调整后的平均差异在大环内酯类、β-内酰胺类和四环素类分别为3.4%(95%CI -4.1%至10.8%;P=0.37)、-1.2%(95%CI -7.9%至5.5%;P=0.72)和-3.3%(95%CI -9.5%至2.8%;P=0.61)。作者认为未能证明未治疗组大环内酯类耐药决定因素出现统计学显著增加。
要点
- 未治疗7-12岁儿童中大环内酯类耐药决定因素调整后平均差异为3.4%(95%CI -4.1%至10.8%;P=0.37)。
- β-内酰胺类和四环素类耐药决定因素调整后平均差异分别为-1.2%和-3.3%,均未达统计学显著。
- 作者认为结果可能与小幅溢出效应一致,但研究把握度不足以检测如此小的差异,需更大规模研究。
核心结论
- 作者认为未能证明阿奇霉素群体给药项目中未治疗组大环内酯类耐药决定因素出现统计学显著增加。
- 作者认为结果可能与小幅溢出效应一致,但本研究把握度不足以检测如此小的差异,需更大规模研究以更好量化这些项目中的潜在溢出效应。
研究设计与样本
- 本研究为整群随机试验的二次分析,比较每半年一次向1-59月龄儿童分发阿奇霉素与安慰剂对儿童死亡率的影响。
- 检测未治疗7-12岁儿童鼻咽样本中大环内酯类耐药遗传决定因素(主要结局)及其他抗生素类别耐药(次要结局)。
- 采用线性回归比较24个月时两组社区层面患病率均值差异,并调整基线患病率。
- 分析纳入30个社区的1103名7-12岁儿童(阿奇霉素组15个社区,安慰剂组15个社区)。
主要发现
- 大环内酯类耐药决定因素患病率经调整后平均差异为3.4%(95%CI -4.1%至10.8%;P=0.37),未达统计学显著。
- β-内酰胺类耐药决定因素患病率经调整后平均差异为-1.2%(95%CI -7.9%至5.5%;P=0.72),未达统计学显著。
- 四环素类耐药决定因素患病率经调整后平均差异为-3.3%(95%CI -9.5%至2.8%;P=0.61),未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究把握度不足以检测小幅溢出效应差异。
- 作者结论指出需更大规模研究以更好量化这些项目中的潜在溢出效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of antibiotic resistance is complicated by the potential for spillover effects from one treated population to another. Azithromycin mass drug administration programs report higher rates of antibiotic resistance among treatment arms in targeted groups. This study aimed to understand the risk of spillover of antibiotic resistance to nontarget groups in these programs. METHODS: Data were used from a cluster-randomized trial comparing the effects of biannual azithromycin and placebo distribution to children 1-59 months old on child mortality rates. Nasopharyngeal samples from untreated children 7-12 years old were tested for genetic determinants of macrolide resistance (primary outcome) and resistance to other antibiotic classes (secondary outcomes). Linear regression was used to compare the community-level mean difference in prevalence by arm at the 24-month time point, adjusting for baseline prevalence. RESULTS: A total of 1103 children 7-12 years old in 30 communities were included in the analysis (15 azithromycin, 15 placebo). The adjusted mean differences in the prevalence of resistance determinants for macrolides, β-lactams, and tetracyclines were 3.4% (95% confidence interval, -4.1% to 10.8%; P = .37), -1.2% (-7.9% to 5.5%; P = .72), and -3.3% (-9.5% to 2.8%; P = .61), respectively. CONCLUSIONS: We were unable to demonstrate a statistically significant increase in macrolide resistance determinants in untreated groups in an azithromycin mass drug administration program. While the result might be consistent with a small spillover effect, this study was not powered to detect such a small difference. Larger studies are warranted to better quantify the potential for spillover effects within these programs.
引用
- Peterson B, Arzika AM, Amza A, et al. Assessment of Spillover of Antimicrobial Resistance to Untreated Children 7-12 Years Old After Mass Drug Administration of Azithromycin for Child Survival in Niger: A Secondary Analysis of the MORDOR Cluster-Randomized Trial. Clin Infect Dis. 2024. PMID: 38739754. doi:10.1093/cid/ciae267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。